Regulatory Framework
The adoption of agentic AI by regulatory bodies represents a significant milestone in institutional governance. In December 2025, the FDA began deploying agentic AI technologies for in-house operations, marking a notable shift in how regulatory agencies approach automation of their core functions. This development reflects growing institutional confidence in autonomous AI systems capable of handling structured decision-making processes within established regulatory workflows.
Institutional Implementation
The FDA’s deployment of agentic AI focuses on automating routine administrative and analytical tasks within the agency’s operations. These systems operate within defined parameters and existing regulatory guidelines, allowing the agency to test autonomous AI capabilities in a controlled environment before considering broader applications to external regulatory decisions.
Governance Implications
This adoption by a major regulatory body signals an evolving relationship between government institutions and autonomous AI systems. The FDA’s use of these technologies in-house establishes practical experience with AI agents in high-stakes environments, informing potential future approaches to regulation of similar technologies across other sectors and agencies.